Literature DB >> 21269585

Acute renal failure in dense deposit disease: complete recovery after combination therapy with immunosuppressant and plasma exchange.

R T Krmar1, U Holtbäck, T Linné, U B Berg, G Celsi, M P Söderberg, A Wernerson, A Szakos, S Larsson, L Skattum, P Bárány.   

Abstract

We describe the clinical course of a female adolescent who was followed because of isolated microhematuria and hypocomplementemia before admission to hospital with a sudden onset of acute renal failure. At presentation, she exhibited complement consumption through the complement alternative pathway (AP) while other serologic tests were negative. Renal biopsy revealed dense deposit disease (DDD) with a crescentic pattern. Intravenous methylprednisolone, followed by plasma exchange (PE), and intravenous cyclophosphamide pulses were started shortly after admission. C3NeF and anti-factor H antibody tests were negative. Serum factor H and I levels were normal as well as factor H activity. Screening for mutation in the factor H gene revealed the H402 allele variant. Clinical remission, defined as normalization in renal function and in the activity levels of the complement AP, was noted at one month post-presentation and throughout the follow-up. A repeat renal biopsy showed the disappearance of crescent formation, whereas electron microscopy revealed no regression in dense transformation of the lamina densa. In summary, our patient was successfully treated with immunosuppressant and PE. The absence of known factors associated with DDD suggests that, in this particular case, other regulatory mechanisms of complement AP might have been involved in the disease process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21269585

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  13 in total

1.  Outcome of membranoproliferative glomerulonephritis and C3-glomerulopathy in children and adolescents.

Authors:  Johannes Holle; Lena Berenberg-Goßler; Kaiyin Wu; Ortraud Beringer; Florian Kropp; Dominik Müller; Julia Thumfart
Journal:  Pediatr Nephrol       Date:  2018-09-20       Impact factor: 3.714

Review 2.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

Review 3.  Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach.

Authors:  An S De Vriese; Sanjeev Sethi; Jens Van Praet; Karl A Nath; Fernando C Fervenza
Journal:  J Am Soc Nephrol       Date:  2015-07-16       Impact factor: 10.121

4.  Successful therapy of C3Nef-positive C3 glomerulopathy with plasma therapy and immunosuppression.

Authors:  Karsten Häffner; Stefan Michelfelder; Martin Pohl
Journal:  Pediatr Nephrol       Date:  2015-05-19       Impact factor: 3.714

5.  Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy.

Authors:  Ozan Ozkaya; Hulya Nalcacioglu; Demet Tekcan; Gurkan Genc; Bilge Can Meydan; B Handan Ozdemir; M Kemal Baysal; Hasan Tahsin Keceligil
Journal:  Pediatr Nephrol       Date:  2014-01-26       Impact factor: 3.714

Review 6.  Treatment options for C3 glomerulopathy.

Authors:  Carla M Nester; Richard J Smith
Journal:  Curr Opin Nephrol Hypertens       Date:  2013-03       Impact factor: 2.894

7.  C3 glomerulopathy: consensus report.

Authors:  Matthew C Pickering; Vivette D D'Agati; Carla M Nester; Richard J Smith; Mark Haas; Gerald B Appel; Charles E Alpers; Ingeborg M Bajema; Camille Bedrosian; Michael Braun; Mittie Doyle; Fadi Fakhouri; Fernando C Fervenza; Agnes B Fogo; Véronique Frémeaux-Bacchi; Daniel P Gale; Elena Goicoechea de Jorge; Gene Griffin; Claire L Harris; V Michael Holers; Sally Johnson; Peter J Lavin; Nicholas Medjeral-Thomas; B Paul Morgan; Cynthia C Nast; Laure-Hélène Noel; D Keith Peters; Santiago Rodríguez de Córdoba; Aude Servais; Sanjeev Sethi; Wen-Chao Song; Paul Tamburini; Joshua M Thurman; Michael Zavros; H Terence Cook
Journal:  Kidney Int       Date:  2013-10-30       Impact factor: 10.612

Review 8.  C3 glomerulopathy and current dilemmas.

Authors:  Naoko Ito; Ryuji Ohashi; Michio Nagata
Journal:  Clin Exp Nephrol       Date:  2016-11-23       Impact factor: 2.801

9.  C3 glomerulopathy in cystic fibrosis: a case report.

Authors:  Domenico Santoro; Rossella Siligato; Carmela Vadalà; Mariacristina Lucanto; Simona Cristadoro; Giovanni Conti; Michele Buemi; Stefano Costa; Ettore Sabadini; Giuseppe Magazzù
Journal:  BMC Nephrol       Date:  2018-03-28       Impact factor: 2.388

Review 10.  Overview of C3 Glomerulopathy.

Authors:  Vimal Master Sankar Raj; Roberto Gordillo; Deepa H Chand
Journal:  Front Pediatr       Date:  2016-05-06       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.